THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO
End of the stabilisation period
ABGSC has in the capacity of stabilisation manager had the ability to carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the market. Stabilisation measures could be carried out on Nasdaq First North Premier Growth Market, in the over-the-counter market or otherwise, at any time during the period which started on the first day of trading in the shares on Nasdaq First North Premier Growth Market, i.e. on
The stabilisation period has ended as of today and no further stabilisation transactions will be carried out.
Detailed below is a summary of the stabilisation transactions carried out by ABGSC during the stabilisation period in accordance with article 5(4) of the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 on Nasdaq First North Premier Growth Market, as previously disclosed in a press release on
Stabilisation information:
Issuer:
Securities: Shares (ISIN: SE0015242896)
Offering size: 14,197,260 shares
Over-allotment option 1,419,725 shares
Offer price:
Ticker:
Stabilisation manager:
Stabilisation
transactions:
Date Quantity, Price Price Price Currency Market
shares (highest) (lowest) (volume place
weighted
average)
First
North
Premier
Growth
Market
First
North
Premier
Growth
Market
This information is information that
Exercise of the over-allotment option
As announced in connection with the Private Placement and listing of the Company's shares on Nasdaq First North Premier Growth Market, certain selling shareholders[(1)] have granted an over-allotment option for 1,419,725 existing shares (corresponding to 10 percent of the transaction) to ABGSC (the "Over-allotment option") that were allocated to investors in connection with the Private Placement. The purpose of the over-allotment option was to facilitate delivery of the over-allotment in the Private Placement and ABGSC's stabilisation measures. ABGSC has acquired 1,063,865 shares in the Company through stabilisation transactions, which means that 1,063,865 shares that ABGSC has borrowed as part of the Over-Allotment Option will be returned to
1.
About Scandinavian Biogas
Scandinavian
For more information, please contact:
Telephone: +46 (0) 70-597 99 38
Email: matti.vikkula@scandinavianbiogas.com
Telephone: +46 (0) 70-043 43 13
Email: anna.budzynski@scandinavianbiogas.com
The Company's Certified Adviser is
Telephone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se
IMPORTANT INFORMATION
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from someone else.
This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the shares. Any investment decision in connection with the private placement must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in
This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of shares or other securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.
In the
The information in this press release may not be forwarded or distributed to any other person and may not be reproduced at all. Any forwarding, distribution, reproduction or disclosure of this information in its entirety or in any part is prohibited. Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.
Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in the Company have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the private placement. Furthermore, it is noted that, notwithstanding the Target Market Assessment,
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.
https://news.cision.com/scandinavian-biogas-fuels-international-ab--publ-/r/information-on-the-over-allotment-option-and-end-of-the-stabilisation-period,c3268866
https://mb.cision.com/Main/1925/3268866/1359844.pdf
(c) 2021 Cision. All rights reserved., source